Volume 107, Issue 5, Pages 1256–1265.e6
Authors:
Lauren Johnson, M.D., M.S.C.E, Mary D. Sammel, Sc.D., Susan Domchek, M.D., Allison Schanne, B.A., Maureen Prewitt, B.S.N., Clarisa Gracia, M.D., M.S.C.E.
Antimüllerian hormone levels are lower in BRCA2 mutation carriers
BRCA2 mutation carriers have antimullerian hormone
(AMH) levels that are significantly lower than healthy
low-risk control women and have increased odds of
having low AMH levels.
Published
Volume 107, Issue 5, Pages 1256–1265.e6
Editorial Office, American Society for Reproductive Medicine
Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.
Please sign in or register for FREE
Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.